Agios Pharmaceuticals, Inc. (AGIO)
AGIO Stock Price Chart
Key Info
| Market Cap | 3.10B |
| Revenue (ttm) | 194.59M |
| Net Income (ttm) | -332.06M |
| Shares Out | 69.14M |
| EPS (ttm) | -4.91 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | December 4 |
| Last Price | $44.70 |
| Previous Close | $45.25 |
| Change ($) | -0.55 |
| Change (%) | -1.22% |
| Day's Open | 45.56 |
| Day's Range | 44.30 - 46.16 |
| Day's Volume | 424,750 |
| 52-Week Range | 31.52 - 55.93 |
AGIO Stock News
Agios' (AGIO) phase III ACTIVATE study evaluating mitapivat for addressing PK deficiency in patients with no regular blood transfusions achieves the primary goal.
CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today ann...
CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today ann...
The FDA confers an orphan drug status on Agios' (AGIO) pyruvate kinase-R activator mitapivat for addressing sickle cell disease. Stock climbs in after-hours trading.
CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today an...
Agios' (AGIO) earnings and revenues fall shy of estimates in the third quarter. The company lifts the lower end of 2020 sales guidance for its leukemia drug Tibsovo.
Agios Pharmaceuticals' (AGIO) CEO Jackie Fouse on Q3 2020 Results - Earnings Call Transcript
Shares of Agios Pharmaceuticals (NASDAQ:AGIO) were unchanged after the company reported Q3 results.
– Third Quarter TIBSOVO® Net Revenue of $31.7 Million; Company Narrows 2020 TIBSOVO® Net U.S. Revenue Guidance to $113–115 Million –
Company to Host Virtual Investor Event and Webcast on Tuesday, December 8, 2020 at 8:00 a.m. ET Company to Host Virtual Investor Event and Webcast on Tuesday, December 8, 2020 at 8:00 a.m. ET
CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today ann...
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today an...
Agios: A Look At Mitapivat In Anaemia, Its Backup Indication
Agios (AGIO) withdraws the regulatory filing for Tibsovo in Europe, which was developed to treat relapsed/refractory acute myeloid leukemia in adult patients with a susceptible IDH1 mutation.
– Agios Continues to Advance Two Phase 3 Combination Trials of TIBSOVO ® in Newly Diagnosed AML Patients –
Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
– Supplemental New Drug Application Planned f or Submission in Q1 2021 –
Andrew Hirsch to Depart Agios and Remain a Strategic Advisor through October 2020 Andrew Hirsch to Depart Agios and Remain a Strategic Advisor through October 2020
Tibsovo sales, after weakness during launch, are ramping nicely.
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock?
CAMBRIDGE, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today a...
Agios to Present at the Virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020
CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today a...
Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q2 2020 Results - Earnings Call Transcript
Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q2 2020 Results - Earnings Call Transcript
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 7.75% and 5.62%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the st...
– Second Quarter TIBSOVO® Net Revenue of $27.6 Million; Company Reiterates 2020 TIBSOVO® Net U.S. Revenue Guidance of $105–115 Million –
Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today ...
Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CAMBRIDGE, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today a...
– Royalty Pharma Acquires Rights to Agios’ Royalty on IDHIFA® Worldwide Net Sales and Outstanding Regulatory Milestone Payments –
– 5 of 8 (63%) Efficacy Evaluable Patients Achieved a Hemoglobin Increase of ≥1.0 g/dL From Baseline –
– Treatment with Mitapivat Induced Hemoglobin (Hb) Increase of ≥1.0 g/dL in 12 of 13 (92%) Evaluable Patients, Including 4 of 4 (100%) α-Thalassemia Patients, During Weeks 4-12 –
Is (AGIO) Outperforming Other Medical Stocks This Year?
The FDA confers an orphan drug status on Agios' (AGIO) pyruvate kinase-R activator mitapivat for addressing patients with thalassemia. Stock rises in after-hours trading.
CAMBRIDGE, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today ...
These four cancer therapeutics stocks are poised to experience long-term growth. An investment in any of these today could bring huge rewards.
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock?
– Vorasidenib Demonstrated Prolonged Disease Control and Encouraging Preliminary Activity with Median Progression-free Survival of 31.4 Months –
Agios Pharmaceuticals, Inc. (AGIO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Is (AGIO) Outperforming Other Medical Stocks This Year?
– TIBSOVO® Is the First and Only IDH1 Inhibitor to Be Evaluated in a Phase 3 Clinical Trial for IDH1-Mutant Cholangiocarcinoma –
As of late, it has definitely been a great time to be an investor Agios Pharmaceuticals
Agios Pharmaceuticals sees its Relative Strength Rating reach the 80-plus level. The post Stocks To Watch: Agios Pharmaceuticals Sees RS Rating Jump To 85 appeared first on Investor's Business...
Agios (AGIO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Agios' (AGIO) loss and revenues better estimates in Q1. The company's wholly owned leukemia drug Tibsovo sees a sequential rise in sales.
Agios Pharmaceuticals, Inc.'s (AGIO) CEO Jacqualyn Fouse on Q1 2020 Results - Earnings Call Transcript
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 65.29% and 182.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for th...
About AGIO
Agios Pharmaceuticals, a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutatio... [Read more...]
| Industry Biotechnology | IPO Date Jul 24, 2013 |
| CEO Jacqualyn Fouse | Employees 536 |
| Stock Exchange NASDAQ | Ticker Symbol AGIO |
Financial Performance
In 2019, AGIO's revenue was $117.91 million, an increase of 24.92% compared to the previous year's $94.39 million. Losses were -$411.47 million, 18.9% more than in 2018.
Analyst Forecasts
The average 12-month stock price forecast for AGIO is 63.83, which is an increase of 42.80% from the latest price.